ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jan 8, 2017
Looking Closely at Zimmer Biomet
Image Source: Zimmer Biomet. Medical technology companies have taken their share of lumps as of late, but the long-term may be too bright for investors to ignore Zimmer Biomet's shares.
Dec 29, 2016
5 Shocking Stock Market Predictions for 2017
Image Source: Claudia Dea. Valuentum: 2017 Is the Year of Evangeline Adams.
Dec 20, 2016
Valuentum’s Dividend Growth Portfolio Retirement Model
Let’s walk through how to use the Valuentum Dividend Growth Portfolio Retirement Model.
Dec 10, 2016
Image: Returns Following the Trump Victory
The stock market is at all-time highs…again. Optimism about what the Trump administration might bring is the main driver, and many are pointing to reduced corporate taxes, translating to higher dividend payments, as reasons to be even more optimistic.
Dec 2, 2016
Tough Month – My Goodness
“After the ‘Trump rally,’ a sobering correction could be coming to the markets, but we didn’t generate a near-12% compound annual return since inception in a dividend growth setting by chasing fads or ups and downs.” – Brian Nelson, CFA
Nov 23, 2016
Valuentum Weekly Web Commentary
Let’s take a look at some of the Valuentum Team’s commentary from the past week.
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.
Oct 26, 2016
EVERYTHING DIVIDENDS + 3 TOP IDEAS
The Valuentum analyst team explains the difference between the adjusted Dividend Cushion ratio and its unadjusted counterpart. The success of the Dividend Growth Newsletter portfolio is covered, and Valuentum's top 3 dividend growth ideas are unveiled. ~13 minutes.
Oct 21, 2016
Pharma Momentum Builds for Johnson & Johnson
Image Source: J&J. Dividend growth giant Johnson & Johnson reported impressive results in the third quarter of 2016 as momentum in its business continues to build.
Oct 15, 2016
Video: An Overview of Our 16-page Stock Research Reports
President of Equity Research, Brian Nelson, walks through how financial advisors and individual investors can get the most out of Valuentum's 16-page equity report.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.